嫩草免费视频丨婷婷六月综合丨日本丰满大乳奶做爰丨手机在线观看免费av丨欧洲在线观看丨久久精品人人做人人爽播放器丨手机看片国产av无码丨国产成人无码a区在线观看视频丨国产欧美成人xxx视频丨亚洲成av人片在线观看无码不卡丨国产精品久久久久乳精品爆丨国产成人亚洲综合色婷婷丨av色图片丨久久精品成人av丨综合色就爱涩涩涩综合婷婷丨国产精品国产三级国产专区51丨亚洲国产三级丨久久亚洲精品国产精品777777丨国产寡妇亲子伦一区二区丨国产精品美女久久久av超清丨岛国av网址丨欧美大片aaaaa免费观看丨一区二区在线观看免费丨日本www在线播放丨欧美视频一区在线

Technoderma Medicines, Inc.is a clinical stage biopharmaceutical company.

The company's current core research and development programs include innovative drugs for the treatment of androgenic alopecia, eczema/atopic dermatitis, psoriasis and lupus. TDM-105795, the world's leading small-molecule drug candidate for the treatment of androgenic alopecia, has now completed 2a clinical trials. TDM-180935, a novel JAK1/TYK2 inhibitor for eczema/atopic dermatitis, has also completed a Phase 1 clinical trial in December 2023 with favorable safety results, and Phase 2 a POC clinical trials are underway in the United States.